Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　– Insights From the ENGAGE AF-TIMI 48 Trial –

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results

“…Among 8157 patients in the present study, 4407 (54.0%) patients fulfilled the enrollment criteria for the ENGAGE AF‐TIMI 48. The mean age and CHADS 2 score were 72 years and 2.8, respectively, in patients in the ENGAGE AF‐TIMI 48 in Japan, and 76 years and 2.8, respectively, in 4407 patients in the present study. The medical history and comorbidities of patients in both studies were similar indicating the patient populations in both groups were similar except for age.…”

Antithrombotic Therapy for Atrial Fibrillation

“…[153][154][155][156]159 90,161,162 distance to OAC clinic, 161,162 self-monitoring/selfmanagement, 91 frequency of INR monitoring, etc. 156 It is also important to note that site-level variation in VKA management has also been demonstrated in RCTs [163][164][165][166][167] and for NOACs. 168 The value of dietary measures to improve anticoagulation control is debatable, and it is perhaps more relevant to maintain a stable dietary habit, avoiding wide changes in the intake of vitamin K. 169 Among patients initiating VKA, the time to achieve therapeutic range has also been related to the likelihood of achieving a subsequently good TTR.…”

Comparison of the Efficacy and Safety of Oral Anticoagulants in East Asians With Atrial Fibrillation

“…In reality, the rate of stroke or systemic embolism was much higher in the warfarin group (4.07%/ year) than in the higher-dose edoxaban group (1.17%/year) among EA patients, and was comparable between the warfarin group (1.56%/year) and the higher-dose edoxaban group (1.47%/year) among Japanese patients. 7 The rate of major bleeding showed a similar trend. It was much higher in the…”